October 31, 2025 — Savara Inc. (Nasdaq: SVRA) has closed its underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares sold through the underwriters’ option, at $4.20 per share.
Savara also sold pre-funded warrants to purchase 7,142,857 shares at $4.199 per warrant to certain investors. The aggregate gross proceeds were approximately $149.5 million before deductions.
Jefferies, Piper Sandler, and Guggenheim Securities were joint book-running managers. Oppenheimer & Co. was the lead manager, with Citizens Capital Markets and H.C. Wainwright & Co. as co-managers.
The offering was made under an existing shelf registration statement filed with the SEC. The final prospectus supplement was filed with the SEC on October 30, 2025. Copies can be obtained from Jefferies LLC, Piper Sandler & Co., or Guggenheim Securities, LLC.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Its lead program, MOLBREEVI*, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Contact Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924 or by email at prospectus@psc.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com
October 31, 2025 — Leads & Copy —
Source: Savara Inc.
